Total Payments
$148,516
2024 Payments
$500.00
Companies
6
Transactions
65
Payment Breakdown by Category
Research$115,051 (77.5%)
Travel$31,167 (21.0%)
Food & Beverage$1,298 (0.9%)
Consulting$999.00 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $115,051 | 22 | 77.5% |
| Travel and Lodging | $31,167 | 23 | 21.0% |
| Food and Beverage | $1,298 | 18 | 0.9% |
| Consulting Fee | $999.00 | 2 | 0.7% |
Payments by Type
Research
$115,051
22 transactions
General
$33,464
43 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharma AG | $139,171 | 37 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $4,508 | 23 | $0 (2019) |
| American Regent | $3,750 | 2 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $500.00 | 1 | $0 (2024) |
| Amgen Inc. | $499.00 | 1 | $0 (2018) |
| Abbott Laboratories | $88.21 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $500.00 | 1 | E.R. Squibb & Sons, L.L.C. ($500.00) |
| 2023 | $24,343 | 4 | Novartis Pharma AG ($20,593) |
| 2022 | $14,838 | 3 | Novartis Pharma AG ($14,838) |
| 2021 | $2,880 | 1 | Novartis Pharma AG ($2,880) |
| 2020 | $24,840 | 4 | Novartis Pharma AG ($24,840) |
| 2019 | $13,294 | 9 | Novartis Pharma AG ($11,640) |
| 2018 | $39,392 | 18 | Novartis Pharma AG ($37,016) |
| 2017 | $28,429 | 25 | Novartis Pharma AG ($27,363) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 10/11/2023 | American Regent | INJECTAFER (Drug) | — | Cash or cash equivalent | $750.00 | Research |
| Study: 1VIT22048 • Category: Iron Deficiency Anemia | ||||||
| 07/11/2023 | Novartis Pharma AG | ENTRESTO (Drug) | — | Cash or cash equivalent | $313.25 | Research |
| Study: PANORAMA-HF Study • Category: CARDIOVASCULAR | ||||||
| 02/06/2023 | Novartis Pharma AG | ENTRESTO (Drug) | — | Cash or cash equivalent | $20,280.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 01/06/2023 | American Regent | INJECTAFER (Drug) | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: 1VIT22048 • Category: Iron Deficiency Anemia | ||||||
| 11/22/2022 | Novartis Pharma AG | ENTRESTO (Drug) | — | Cash or cash equivalent | $465.64 | Research |
| Study: PANORAMA-HF Study • Category: CARDIOVASCULAR | ||||||
| 08/28/2022 | Novartis Pharma AG | ENTRESTO (Drug) | Travel and Lodging | In-kind items and services | $14,319.59 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/25/2022 | Novartis Pharma AG | ENTRESTO (Drug) | Travel and Lodging | In-kind items and services | $52.86 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/03/2021 | Novartis Pharma AG | ENTRESTO (Drug) | — | Cash or cash equivalent | $2,880.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 12/15/2020 | Novartis Pharma AG | LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) | — | Cash or cash equivalent | $4,440.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 11/03/2020 | Novartis Pharma AG | LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) | — | Cash or cash equivalent | $4,320.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 08/25/2020 | Novartis Pharma AG | LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) | — | Cash or cash equivalent | $6,480.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 01/22/2020 | Novartis Pharma AG | LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) | — | Cash or cash equivalent | $9,600.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 11/22/2019 | Abbott Laboratories | CentriMag (Device) | Food and Beverage | In-kind items and services | $88.21 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 11/17/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Travel and Lodging | In-kind items and services | $539.55 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/17/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Travel and Lodging | Cash or cash equivalent | $212.05 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/17/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $112.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/17/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $49.95 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/16/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Travel and Lodging | In-kind items and services | $641.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/02/2019 | Novartis Pharma AG | LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) | — | Cash or cash equivalent | $6,000.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 04/02/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $10.57 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/18/2019 | Novartis Pharma AG | LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) | — | Cash or cash equivalent | $5,640.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 11/11/2018 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $507.00 | General |
| 11/11/2018 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $245.37 | General |
| 11/11/2018 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $218.17 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CLCZ696B2319 | Novartis Pharma AG | $110,522 | 18 |
| 1VIT22048 | American Regent | $3,750 | 2 |
| PANORAMA-HF Study | Novartis Pharma AG | $778.89 | 2 |
About Dr. Robert Shaddy, MD
Dr. Robert Shaddy, MD is a Pediatrics healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508975749.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Shaddy, MD has received a total of $148,516 in payments from pharmaceutical and medical device companies, with $500.00 received in 2024. These payments were reported across 65 transactions from 6 companies. The most common payment nature is "" ($115,051).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Cardiology, Pediatric Cardiology
- Location Philadelphia, PA
- Active Since 08/30/2006
- Last Updated 04/16/2013
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1508975749
Products in Payments
- LCZ696B (Drug) $64,380
- ENTRESTO (Drug) $40,942
- LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) $36,480
- INJECTAFER (Drug) $3,750
- Kyprolis (Biological) $499.00
- CentriMag (Device) $88.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Philadelphia
Matthew Gillespie, M.d, M.D
Pediatrics — Payments: $1.5M
Pediatrics $1.5M
Stephan Grupp, M.d, M.D
Pediatrics — Payments: $472,209
Pediatrics $472,209
Oscar Mayer, M.d, M.D
Pediatrics — Payments: $270,148
Pediatrics $270,148
Michael Levine, Md, MD
Pediatrics — Payments: $137,530
Pediatrics $137,530
Michael Grunstein, M.d, M.D
Pediatrics — Payments: $133,646
Pediatrics $133,646
Craig Alter, M.d, M.D
Pediatrics — Payments: $114,704
Pediatrics $114,704